UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Therapeutic Antigen-Presenting Cell-Targeting DNA Vaccine VB10.16 in HPV16-Positive High-Grade Cervical Intraepithelial Neoplasia: Results from a Phase I/IIa Trial

Clinical cancer research, 2022-11, Vol.28 (22), p.4885-4892

2022

Volltextzugriff (PDF)

Antibody-mediated delivery of T-cell epitopes to antigen-presenting cells induce strong CD4 and CD8 T-cell responses

Vaccine, 2021-03, Vol.39 (11), p.1583-1592

2021

Volltextzugriff (PDF)

Delivery of Antigen to CD40 Induces Protective Immune Responses against Tumors

Journal of Immunology, 2007-04, Vol.178 (7), p.4169-4176

2007

Volltextzugriff (PDF)

Naive idiotope-specific B and T cells collaborate efficiently in the absence of dendritic cells

The Journal of immunology (1950), 2014-05, Vol.192 (9), p.4174-4183

2014

Volltextzugriff (PDF)

667 Predictive value of circulating tumor DNA in patients with advanced HPV16-positive cervical cancer treated with VB10.16 in combination with atezolizumab

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A757-A757

2023

Volltextzugriff (PDF)

Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno‐free CTS Immune Cell Serum Replacement

Clinical & translational immunology, 2015-01, Vol.4 (1), p.e31-n/a

2015

Volltextzugriff (PDF)

Novel APC-like properties of human NK cells directly regulate T cell activation

The Journal of clinical investigation, 2004-12, Vol.114 (11), p.1612-1623

2004

Volltextzugriff (PDF)

Xeno-free serum replacement for ex vivo culture and expansion of T cells

Journal for immunotherapy of cancer, 2014-11, Vol.2 (S3), p.P37-P37, Article P37

2014

Volltextzugriff (PDF)

Recombinant antibodies for delivery of antigen: a single loop between β-strands in the constant region can accommodate long, complex and tandem T cell epitopes

International immunology, 2008-03, Vol.20 (3), p.295-306

2008

Volltextzugriff (PDF)

Cutting Edge: Link Between Innate and Adaptive Immunity: Toll-Like Receptor 2 Internalizes Antigen for Presentation to CD4+ T Cells and Could Be an Efficient Vaccine Target

The Journal of immunology (1950), 2003-07, Vol.171 (1), p.32-36

2003

Volltextzugriff (PDF)

Human receptors of innate immunity (CD14, TLR2) are promising targets for novel recombinant immunoglobulin-based vaccine candidates

Vaccine, 2007-06, Vol.25 (24), p.4723-4734

2007

Volltextzugriff (PDF)

A mouse Cκ‐specific T cell clone indicates that DC‐SIGN is an efficient target for antibody‐mediated delivery of T cell epitopes for MHC class II presentation

International immunology, 2002-12, Vol.14 (12), p.1423-1430

2002

Volltextzugriff (PDF)

Expression of SH2D2A in T-cells is regulated both at the transcriptional and translational level

Molecular immunology, 2008-04, Vol.45 (8), p.2380-2390

2008

Volltextzugriff (PDF)

Human CD14 is an efficient target for recombinant immunoglobulin vaccine constructs that deliver T cell epitopes

Journal of leukocyte biology, 2005-03, Vol.77 (3), p.303-310

2005

Volltextzugriff (PDF)

Abstract A003: High-throughput TCR sequencing demonstrates induction of long-lasting HPV16-specific T cell responses in VB10.16 vaccinated advanced cervical cancer patients

Cancer immunology research, 2023-12, Vol.11 (12_Supplement), p.A003-A003

2023

Volltextzugriff (PDF)

Abstract 2256: Combination of neoantigen DNA plasmid vaccine VB10.NEO and NKTR-214, a CD122-biased immunostimulatory cytokine, induces strong neoantigen-specific T cell responses and sustained tumor regression in pre-clinical models

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.2256-2256

2019

Volltextzugriff (PDF)

Abstract 5003: Vaccibody DNA vaccine platform VB10.NEO induces strong neo-antigen specific CD8+ T cell responses critical to cure established tumors in pre-clinical models

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.5003-5003

2019

Volltextzugriff (PDF)

Abstract CT209: Safety, efficacy and immunogenicity of VB10.16, a therapeutic DNA vaccine targeting human papillomavirus (HPV) 16 E6 and E7 proteins for high grade cervical intraepithelial neoplasia (CIN 2/3): 6-month data from an exploratory open-label phase I/2a trial

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT209-CT209

2019

Volltextzugriff (PDF)

2022-RA-447-ESGO Efficacy and safety of VB10.16, a therapeutic DNA vaccine specifically targeting antigen-cell presenting cells, in combination with atezolizumab in patients with advanced HPV16-positive cervical cancer: results from a pre-planned interim analysis

International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A12-A12

2022

Volltextzugriff (PDF)

Isolation and Expansion of Antigen-Specific Mouse T cells using Dynabeads® (85.9)

The Journal of immunology (1950), 2010-04, Vol.184 (1_Supplement), p.85-85.9

2010

Volltextzugriff (PDF)

Abstract CT217: An open-label, Phase I/IIa study of VB10.NEO (DIRECT-01) in combination with checkpoint blockade in patients with locally advanced or metastatic solid tumors including melanoma, NSCLC, renal cell carcinoma, urothelial cancer or SSCHN

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT217-CT217

2019

Volltextzugriff (PDF)

Antibody‐mediated delivery of antigen to chemokine receptors on antigen‐presenting cells results in enhanced CD4+ T cell responses

European journal of immunology, 2003-11, Vol.33 (11), p.3101-3108

2003

Volltextzugriff (PDF)

Abstract CT274: Individualized APC targeting VB10.NEO cancer vaccines induce broad neoepitope-specific CD8 T cell responses in patients with advanced or metastatic solid tumors: interim results from a phase 1/2a trial

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT274-CT274

2023

Volltextzugriff (PDF)

Naïve anti-Id B cells and Id-specific CD4+ T cells collaborate efficiently to non infectious antigens in the absence of dendritic cells. (122.12)

The Journal of immunology (1950), 2012-05, Vol.188 (1_Supplement), p.122-122.12

2012

Volltextzugriff (PDF)

CTS™ immune cell SR for serum free culture and expansion of human T cells

Cytotherapy (Oxford, England), 2015-06, Vol.17 (6), p.S77-S77

2015

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(35)

Sprache

Englisch
(35)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(15)
Science & Technology
(15)
Immunology
(13)
Humans
(9)
Animals
(7)
Mice
(7)
Antigen Presentation
(6)
Cd4-Positive T-Lymphocytes - Immunology
(6)
Antigens
(5)
Lymphocytes
(5)
Antibodies, Monoclonal - Immunology
(4)
Antigen-Presenting Cells - Immunology
(4)
Cell Line
(4)
Immunotherapy
(4)
Medicine, Research & Experimental
(4)
Mice, Inbred Balb C
(4)
Research & Experimental Medicine
(4)
Vaccines
(4)
Antibodies
(3)
Cell Proliferation
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A Therapeutic Antigen-Presenting Cell-Targeting DNA Vaccine VB10.16 in HPV16-Positive High-Grade Cervical Intraepithelial Neoplasia: Results from a Phase I/IIa Trial

Antibody-mediated delivery of T-cell epitopes to antigen-presenting cells induce strong CD4 and CD8 T-cell responses

Delivery of Antigen to CD40 Induces Protective Immune Responses against Tumors

Naive idiotope-specific B and T cells collaborate efficiently in the absence of dendritic cells

667 Predictive value of circulating tumor DNA in patients with advanced HPV16-positive cervical cancer treated with VB10.16 in combination with atezolizumab

Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno‐free CTS Immune Cell Serum Replacement

Novel APC-like properties of human NK cells directly regulate T cell activation

Xeno-free serum replacement for ex vivo culture and expansion of T cells

Recombinant antibodies for delivery of antigen: a single loop between β-strands in the constant region can accommodate long, complex and tandem T cell epitopes

Cutting Edge: Link Between Innate and Adaptive Immunity: Toll-Like Receptor 2 Internalizes Antigen for Presentation to CD4+ T Cells and Could Be an Efficient Vaccine Target

Human receptors of innate immunity (CD14, TLR2) are promising targets for novel recombinant immunoglobulin-based vaccine candidates

A mouse Cκ‐specific T cell clone indicates that DC‐SIGN is an efficient target for antibody‐mediated delivery of T cell epitopes for MHC class II presentation

Expression of SH2D2A in T-cells is regulated both at the transcriptional and translational level

Human CD14 is an efficient target for recombinant immunoglobulin vaccine constructs that deliver T cell epitopes

Abstract A003: High-throughput TCR sequencing demonstrates induction of long-lasting HPV16-specific T cell responses in VB10.16 vaccinated advanced cervical cancer patients

Abstract 2256: Combination of neoantigen DNA plasmid vaccine VB10.NEO and NKTR-214, a CD122-biased immunostimulatory cytokine, induces strong neoantigen-specific T cell responses and sustained tumor regression in pre-clinical models

Abstract 5003: Vaccibody DNA vaccine platform VB10.NEO induces strong neo-antigen specific CD8+ T cell responses critical to cure established tumors in pre-clinical models

Abstract CT209: Safety, efficacy and immunogenicity of VB10.16, a therapeutic DNA vaccine targeting human papillomavirus (HPV) 16 E6 and E7 proteins for high grade cervical intraepithelial neoplasia (CIN 2/3): 6-month data from an exploratory open-label phase I/2a trial

2022-RA-447-ESGO Efficacy and safety of VB10.16, a therapeutic DNA vaccine specifically targeting antigen-cell presenting cells, in combination with atezolizumab in patients with advanced HPV16-positive cervical cancer: results from a pre-planned interim analysis

Isolation and Expansion of Antigen-Specific Mouse T cells using Dynabeads® (85.9)

Abstract CT217: An open-label, Phase I/IIa study of VB10.NEO (DIRECT-01) in combination with checkpoint blockade in patients with locally advanced or metastatic solid tumors including melanoma, NSCLC, renal cell carcinoma, urothelial cancer or SSCHN

Antibody‐mediated delivery of antigen to chemokine receptors on antigen‐presenting cells results in enhanced CD4+ T cell responses

Abstract CT274: Individualized APC targeting VB10.NEO cancer vaccines induce broad neoepitope-specific CD8 T cell responses in patients with advanced or metastatic solid tumors: interim results from a phase 1/2a trial

Naïve anti-Id B cells and Id-specific CD4+ T cells collaborate efficiently to non infectious antigens in the absence of dendritic cells. (122.12)

CTS™ immune cell SR for serum free culture and expansion of human T cells

Suchergebnisse filtern